目前对非小细胞肺癌中不常见的EGFR突变的管理
Jonathan Q Trinh1, Omar Abughanimeh2
1Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States.
Current problems in cancer
|February 4, 2024
概括
在非小细胞肺癌 (NSCLC) 中不常见的表皮生长因子受体 (EGFR) 突变需要特定的治疗策略. 本综述详细介绍了这些罕见的EGFR变异及其基于证据的管理,以优化患者护理.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 表皮生长因子受体 (EGFR) 突变是非小细胞肺癌 (NSCLC) 的关键驱动因素.
- 常见的EGFR突变包括19号外原体的删除和21号外原体中的L858R.
- 不常见的EGFR突变占NSCLC所有EGFR变化的10-15%.
研究的目的:
- 审查NSCLC中不常见的EGFR突变.
- 分析这些不同的变体的治疗结果.
- 为罕见的EGFR突变提供基于证据的管理指南.
主要方法:
- 关于不常见EGFR突变的当前研究的文献综述.
- 对治疗反应和临床结果的分析.
- 综合证据,制定管理准则.
主要成果:
- 识别了频繁不常见的EGFR突变:G719X (外显子18),L861Q (外显子21),S768I (外显子20),以及外显子20的插入/重复.
- 对每个变种的具体治疗疗效进行了检查.
- 根据突变类型,治疗反应的突出变化.
结论:
- 了解不常见的EGFR突变对于个性化NSCLC治疗至关重要.
- 为了在患有罕见EGFR变异的患者中获得最佳结果,需要量身定制的治疗策略.
- 本综述为在NSCLC中患有不常见EGFR突变的患者的管理提供了一个框架.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
